Financial, market and economic news

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB

NEW YORK, Nov. 22, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ:  BIIB).   Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Biogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On November 6, 2020, Biogen issued a press release announcing that the Company’s proposed Alzheimer’s therapy had failed to win support from the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee.  Specifically, the press release disclosed that the Advisory Committee “voted 1 yes, 8 no and 2 uncertain on the question, …

Full story available on Benzinga.com

Read More

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More

Privacy & Cookies Policy